GH Research PLC (GHRS) News
Filter GHRS News Items
GHRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GHRS News Highlights
- GHRS's 30 day story count now stands at 3.
- Over the past 6 days, the trend for GHRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NOTE are the most mentioned tickers in articles about GHRS.
Latest GHRS News From Around the Web
Below are the latest news stories about GH RESEARCH PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
15 Best Falling Stocks To Buy NowIn this article, we will take a detailed look at the 15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5 Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive note as the Fed’s indication of coming rate cuts have infused a […] |
GH Research Drags Down Psychedelic Drug Stocks Index By 7%The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. |
GH Research Reports Third Quarter Financial Results and Provides Business UpdatesDUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates. Third Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $228.7 million as of September 30, 2023, compar |
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant DepressionDUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD). Development Strategy As previously announced, following successful completion of our Phase 1/2 tr |
GH Research Reports Second Quarter 2023 Financial Results and Provides Business UpdatesDUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cas |
Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
‘It’s Really a Brain Chemistry Issue’: Elon Musk Embraces Ketamine in the Battle Against Depression — Here Are 2 Psychedelic Stocks That Analysts LikeThinking outside the box has been a hallmark of Elon Musk’s behavior, and now you might be curious about how he actually reaches those ‘out of the box’ thought patterns. Musk has recently been touting the credentials of ketamine, an anesthetic known for its dissociative qualities. The Tesla CEO has said that he occasionally indulges in microdosing of the drug, believing it to be a better choice than traditional antidepressants for treating depression. Musk has also mentioned experiencing depress |
The 3 Best Psychedelic Stocks to Buy NowPsychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health space. Consumers are increasingly interested in mental health and overall awareness is increasing. Mental health advocates have long touted their benefits and favored their mainstream acceptance. Pharmaceutical firms and other traditional healt |